{"id":"https://openalex.org/W4200329440","doi":"https://doi.org/10.3791/56084-v","title":"Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients","display_name":"Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients","publication_year":2017,"publication_date":"2017-10-15","ids":{"openalex":"https://openalex.org/W4200329440","doi":"https://doi.org/10.3791/56084-v"},"language":"en","primary_location":{"id":"doi:10.3791/56084-v","doi":"https://doi.org/10.3791/56084-v","is_oa":false,"landing_page_url":"https://doi.org/10.3791/56084-v","pdf_url":null,"source":{"id":"https://openalex.org/S199738284","display_name":"Journal of Visualized Experiments","issn_l":"1940-087X","issn":["1940-087X","2834-8400"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320416","host_organization_name":"MyJOVE","host_organization_lineage":["https://openalex.org/P4310320416"],"host_organization_lineage_names":["MyJOVE"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Visualized Experiments","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028105305","display_name":"Elena K. Schneider\u2010Futschik","orcid":"https://orcid.org/0000-0001-6044-4824","observed_orcids":["https://orcid.org/0000-0001-6044-4824"]},"institutions":[{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Elena K. Schneider","raw_affiliation_strings":["Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University","institution_ids":["https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000779587","display_name":"Felisa Reyes\u2010Ortega","orcid":"https://orcid.org/0000-0003-2102-7432","observed_orcids":["https://orcid.org/0000-0003-2102-7432"]},"institutions":[{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Felisa Reyes-Ortega","raw_affiliation_strings":["Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University","institution_ids":["https://openalex.org/I56590836"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jian Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Jian Li","raw_affiliation_strings":["Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University","Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University","institution_ids":["https://openalex.org/I56590836"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5020748618","display_name":"Tony Velkov","orcid":"https://orcid.org/0000-0002-0017-7952","observed_orcids":["https://orcid.org/0000-0002-0017-7952"]},"institutions":[{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Tony Velkov","raw_affiliation_strings":["Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University","institution_ids":["https://openalex.org/I56590836"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I56590836"],"apc_list":null,"apc_paid":null,"fwci":0.5739,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.63780907,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":null,"issue":"128","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.92330002784729,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T11460","display_name":"Analytical Methods in Pharmaceuticals","score":0.92330002784729,"subfield":{"id":"https://openalex.org/subfields/1602","display_name":"Analytical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.0215000007301569,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.007799999788403511,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ivacaftor","display_name":"ivacaftor","score":0.9679999947547913},{"id":"https://openalex.org/keywords/lumacaftor","display_name":"lumacaftor","score":0.996999979019165},{"id":"https://openalex.org/keywords/cystic-fibrosis","display_name":"cystic fibrosis","score":0.9570000171661377},{"id":"https://openalex.org/keywords/cftr-modulators","display_name":"CFTR modulators","score":0.7739999890327454},{"id":"https://openalex.org/keywords/lc-ms-ms-method-optimization","display_name":"LC-MS/MS method optimization","score":0.8539999723434448},{"id":"https://openalex.org/keywords/body-fluids","display_name":"biological fluids","score":0.824999988079071},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8560000061988831},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7419999837875366},{"id":"https://openalex.org/keywords/exposure-response-relationship","display_name":"exposure-response relationship","score":0.7419999837875366}],"concepts":[{"id":"https://openalex.org/C2776502428","wikidata":"https://www.wikidata.org/wiki/Q6095693","display_name":"Ivacaftor","level":4,"score":0.9932469129562378},{"id":"https://openalex.org/C2776938444","wikidata":"https://www.wikidata.org/wiki/Q178194","display_name":"Cystic fibrosis","level":2,"score":0.688370406627655},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.6014957427978516},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5973994135856628},{"id":"https://openalex.org/C179998833","wikidata":"https://www.wikidata.org/wiki/Q381233","display_name":"High-performance liquid chromatography","level":2,"score":0.5365450978279114},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49601873755455017},{"id":"https://openalex.org/C2778428886","wikidata":"https://www.wikidata.org/wiki/Q420470","display_name":"Cystic fibrosis transmembrane conductance regulator","level":3,"score":0.4859074652194977},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4199276268482208},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3853895664215088},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2914848327636719},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1929704248905182}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.3791/56084-v","doi":"https://doi.org/10.3791/56084-v","is_oa":false,"landing_page_url":"https://doi.org/10.3791/56084-v","pdf_url":null,"source":{"id":"https://openalex.org/S199738284","display_name":"Journal of Visualized Experiments","issn_l":"1940-087X","issn":["1940-087X","2834-8400"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320416","host_organization_name":"MyJOVE","host_organization_lineage":["https://openalex.org/P4310320416"],"host_organization_lineage_names":["MyJOVE"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Visualized Experiments","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8560000061988831}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3099775071","https://openalex.org/W4321378234","https://openalex.org/W4399980990","https://openalex.org/W2540482631","https://openalex.org/W4403906263","https://openalex.org/W6996035351","https://openalex.org/W3085052984","https://openalex.org/W4396839781","https://openalex.org/W4412162332","https://openalex.org/W7213270819"],"abstract_inverted_index":{"Defects":[0],"in":[1,79,82],"the":[2,10,37,42,57,67,71,107,121,125,195,215,235],"cystic":[3,13],"fibrosis":[4,14],"trans-membrane":[5],"conductance":[6],"regulator":[7],"(CFTR)":[8],"are":[9,28],"cause":[11],"of":[12,41,51,59,70,73,110,114,127,183,189,217,221,229,238],"(CF),":[15],"a":[16,49,111,128,145,218],"disease":[17],"with":[18],"life-threatening":[19],"pulmonary":[20],"manifestations.":[21],"Ivacaftor":[22],"(IVA)":[23],"and":[24,39,56,61,77,98,144],"ivacaftor-lumacaftor":[25,88],"(LUMA)":[26],"combination":[27,89],"two":[29],"new":[30],"breakthrough":[31,240],"CF":[32,241],"drugs":[33],"that":[34],"directly":[35],"modulate":[36],"activity":[38],"trafficking":[40],"defective":[43],"CFTR-protein.":[44],"However,":[45,104],"there":[46],"is":[47,212],"still":[48],"dearth":[50],"understanding":[52],"on":[53],"pharmacokinetic/pharmacodynamic":[54],"parameters":[55],"pharmacology":[58],"ivacaftor":[60,86],"lumacaftor.":[62],"The":[63,187],"HPLC-MS":[64,196],"technique":[65],"for":[66,214,232],"simultaneous":[68],"analysis":[69,109,197,216],"concentrations":[72],"ivacaftor,":[74],"hydroxymethyl-ivacaftor,":[75],"ivacaftor-carboxylate,":[76],"lumacaftor":[78],"biological":[80],"fluids":[81],"patients":[83],"receiving":[84],"standard":[85],"or":[87],"therapy":[90],"has":[91,119],"previously":[92],"been":[93],"developed":[94],"by":[95],"our":[96,117],"group":[97,118],"partially":[99],"validated":[100],"to":[101,105,193,205],"FDA":[102],"standards.":[103],"allow":[106],"high-throughput":[108],"larger":[112],"number":[113],"patient":[115,222],"samples,":[116],"optimized":[120],"reported":[122],"method":[123,226],"through":[124],"use":[126],"smaller":[129],"pore":[130],"size":[131],"reverse-phase":[132],"chromatography":[133],"column":[134],"(2.6":[135],"\u00b5m,":[136],"C8":[137],"100":[138],"\u00c5;":[139],"50":[140],"x":[141],"2.1":[142],"mm)":[143],"gradient":[146],"solvent":[147],"system":[148],"(0-1":[149],"min:":[150,154,158,164,168,173,177],"40%":[151,180],"B;":[152,156,162,166,175],"1-2":[153],"40-70%":[155],"2-2.7":[157],"held":[159,178],"at":[160,179],"70%":[161],"2.7-2.8":[163],"70-90%":[165],"2.8-4.0":[167],"90%":[169],"B":[170],"washing;":[171],"4.0-4.1":[172],"90-40%":[174],"4.1-6.0":[176],"B)":[181],"instead":[182],"an":[184],"isocratic":[185],"elution.":[186],"goal":[188],"this":[190],"study":[191],"was":[192],"reduce":[194],"time":[198],"per":[199,209],"sample":[200],"dramatically":[201],"from":[202],"~15":[203],"min":[204,208],"only":[206],"6":[207],"sample,":[210],"which":[211],"essential":[213],"large":[219],"amount":[220],"samples.":[223],"This":[224],"expedient":[225],"will":[227],"be":[228],"considerable":[230],"utility":[231],"studies":[233],"into":[234],"exposure-response":[236],"relationships":[237],"these":[239],"drugs.":[242]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2021-12-31T00:00:00"}